ACA
TGTX icon

Avoro Capital Advisors’s TG Therapeutics TGTX Stock Holding History

Avoro Capital Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-800,000
Closed -$7.87M – 51
2020
Q1 		$7.87M Sell
800,000
-200,000
-20% -$2.53M 0.27% 36
2019
Q4 		$11.1M Buy
+1,000,000
New +$7.6M 0.33% 26
2019
Q1 		– Sell
-4,750,000
Closed -$19.5M – 35
2018
Q4 		$19.5M Buy
4,750,000
+549,969
+13% +$2.73M 1.16% 17
2018
Q3 		$23.5M Sell
4,200,031
-750,000
-15% -$8.57M 1.08% 20
2018
Q2 		$65.1M Sell
4,950,031
-279,588
-5% -$3.85M 2.51% 15
2018
Q1 		$74.3M Buy
5,229,619
+1,935,156
+59% +$24.7M 3.55% 9
2017
Q4 		$27M Buy
+3,294,463
New +$28.8M 1.75% 19

Other funds holding TGTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Avoro Capital Advisors's TGTX Position: Q2 2020 in Review

Avoro Capital Advisors sold out of TG Therapeutics (TGTX) in Q2 2020, closing a stake of 800,000 shares — an estimated $7.87M sold.

Avoro Capital Advisors first reported a position in TGTX in Q4 2017 and held it in 7 quarters. The position peaked at $74.3M in Q1 2018. 175 funds tracked by Wall St. Rank hold TGTX as of Q2 2020.

  • Avoro Capital Advisors reported no remaining TG Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Avoro Capital Advisors sold 800,000 TG Therapeutics shares in Q2 2020, an estimated $7.87M.
  • Avoro Capital Advisors first reported a position in TG Therapeutics in Q4 2017 and held it in 7 quarters.
  • Avoro Capital Advisors's TG Therapeutics position peaked at $74.3M in Q1 2018.
  • 175 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2020.

Based on Avoro Capital Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.